FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * PIMSTONE SIMON N. 2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [ XENE ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)
200 - 3650 GILMORE WAY		 3. Date of Earliest Transaction (MM/DD/YYYY)
3/7/2023
(Street)
BURNABY, A1 V5G 4W8
(City)        (State)        (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares  3/7/2023    M    41152  A $2.68 (1) 47152  D   
Common Shares  3/7/2023    F    2160  D $37.13 (2) 44992  D   
Common Shares  3/7/2023    S    10990  D $37.01 (3) 34002  D   
Common Shares  3/7/2023    M    30864  A $2.59 (1) 64866  D   
Common Shares  3/7/2023    F    1618  D $37.13 (2) 63248  D   
Common Shares  3/7/2023    S    8242  D $36.94 (4) 55006  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $2.68 (1) 3/7/2023    M        41152    (5) 3/10/2023 (6) Common Shares  41152  $0.00  0  D   
Stock Option (Right to Buy)  $2.59 (1) 3/7/2023    M        30864    (5) 3/9/2023  Common Shares  30864  $0.00  0  D   

Explanation of Responses:
(1)  The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
(2)  Represents the closing price of the Company's common shares on March 6, 2023 for purposes of net settlement calculations.
(3)  The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.93 to $37.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
(4)  The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.89 to $37.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
(5)  The shares subject to the options are fully vested and exercisable.
(6)  Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
PIMSTONE SIMON N.
200 - 3650 GILMORE WAY
BURNABY, A1 V5G 4W8		 X



Signatures
/s/ Cassandra Robinson, Power of Attorney 3/9/2023
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From May 2023 to Jun 2023 Click Here for more Xenon Pharmaceuticals Charts.
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From Jun 2022 to Jun 2023 Click Here for more Xenon Pharmaceuticals Charts.